Argenx Nv Adr Stock Fundamentals
| ARGX Stock | USD 604.96 23.75 4.09% |
argenx NV ADR fundamentals help investors to digest information that contributes to Argenx NV's financial success or failures. It also enables traders to predict the movement of Argenx Stock. The fundamental analysis module provides a way to measure Argenx NV's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Argenx NV stock.
Argenx |
argenx NV ADR Company Current Valuation Analysis
Argenx NV's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Argenx NV Current Valuation | 32.52 B |
Most of Argenx NV's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, argenx NV ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, argenx NV ADR has a Current Valuation of 32.52 B. This is 126.41% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 95.62% lower than that of the firm.
argenx NV ADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Argenx NV's current stock value. Our valuation model uses many indicators to compare Argenx NV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Argenx NV competition to find correlations between indicators driving Argenx NV's intrinsic value. More Info.argenx NV ADR is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Argenx NV's earnings, one of the primary drivers of an investment's value.Argenx Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Argenx NV's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Argenx NV could also be used in its relative valuation, which is a method of valuing Argenx NV by comparing valuation metrics of similar companies.Argenx NV is currently under evaluation in current valuation category among its peers.
Argenx Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | -0.0016 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 32.52 B | ||||
| Shares Outstanding | 60.76 M | ||||
| Shares Owned By Institutions | 57.84 % | ||||
| Number Of Shares Shorted | 2.06 M | ||||
| Price To Earning | 5.54 X | ||||
| Price To Book | 6.42 X | ||||
| Price To Sales | 15.92 X | ||||
| Revenue | 1.23 B | ||||
| Gross Profit | 1.04 B | ||||
| EBITDA | (216.02 M) | ||||
| Net Income | (425.05 M) | ||||
| Cash And Equivalents | 2.6 B | ||||
| Cash Per Share | 47.17 X | ||||
| Total Debt | 20 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.07 X | ||||
| Book Value Per Share | 90.85 X | ||||
| Cash Flow From Operations | (420.33 M) | ||||
| Short Ratio | 7.69 X | ||||
| Earnings Per Share | 12.79 X | ||||
| Target Price | 771.34 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 35.86 B | ||||
| Total Asset | 4.54 B | ||||
| Retained Earnings | (2.4 B) | ||||
| Working Capital | 3.7 B | ||||
| Current Asset | 78.94 M | ||||
| Current Liabilities | 30.84 M | ||||
| Net Asset | 4.54 B |
About Argenx NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze argenx NV ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Argenx NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of argenx NV ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argenx Se is traded on NASDAQ Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Argenx Stock Analysis
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.